MA29730B1 - Detection d'un antigene cible independamment de la presence ou de l'absence d'un anticorps therapeutique correspondant - Google Patents

Detection d'un antigene cible independamment de la presence ou de l'absence d'un anticorps therapeutique correspondant

Info

Publication number
MA29730B1
MA29730B1 MA30617A MA30617A MA29730B1 MA 29730 B1 MA29730 B1 MA 29730B1 MA 30617 A MA30617 A MA 30617A MA 30617 A MA30617 A MA 30617A MA 29730 B1 MA29730 B1 MA 29730B1
Authority
MA
Morocco
Prior art keywords
target antigen
therapeutic antibody
absence
detection
therapeutic
Prior art date
Application number
MA30617A
Other languages
English (en)
Inventor
Helmut Lenz
Werner Scheuer
Martina Thier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA29730B1 publication Critical patent/MA29730B1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE LES ANTICORPS THÉRAPEUTIQUES. L'INVENTION CONCERNE EN PARTICULIER UNE MÉTHODE DE DÉTECTION DE L'ANTIGÈNE CIBLE D'UN ANTICORPS THÉRAPEUTIQUE DANS UN ÉCHANTILLON, CONSISTANT A) À OBTENIR L'ÉCHANTILLON À ANALYSER, B) À INCUBER LEDIT ÉCHANTILLON AVEC L'ANTICORPS THÉRAPEUTIQUE DANS DES CONDITIONS ADAPTÉES POUR LA LIAISON DE L'ANTICORPS THÉRAPEUTIQUE À L'ANTIGÈNE CIBLE, UN COMPLEXE ANTIGÈNE CIBLE-ANTICORPS THÉRAPEUTIQUE ÉTANT AINSI FORMÉ, ET C) À DÉTECTER LE COMPLEXE FORMÉ AU COURS DE L'ÉTAPE (B).
MA30617A 2005-07-06 2008-02-01 Detection d'un antigene cible independamment de la presence ou de l'absence d'un anticorps therapeutique correspondant MA29730B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP06004447 2006-03-06

Publications (1)

Publication Number Publication Date
MA29730B1 true MA29730B1 (fr) 2008-09-01

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30617A MA29730B1 (fr) 2005-07-06 2008-02-01 Detection d'un antigene cible independamment de la presence ou de l'absence d'un anticorps therapeutique correspondant

Country Status (19)

Country Link
US (1) US20070009976A1 (fr)
EP (2) EP1902315A1 (fr)
JP (1) JP2008545145A (fr)
KR (1) KR20080016939A (fr)
AR (1) AR053948A1 (fr)
AU (1) AU2006265275A1 (fr)
BR (1) BRPI0612591A2 (fr)
CA (1) CA2613187A1 (fr)
CR (1) CR9635A (fr)
EC (1) ECSP088081A (fr)
IL (1) IL188317A0 (fr)
MA (1) MA29730B1 (fr)
MX (1) MX2008000277A (fr)
MY (1) MY157955A (fr)
NO (1) NO20076662L (fr)
NZ (1) NZ564471A (fr)
RU (1) RU2008103608A (fr)
TW (1) TWI312864B (fr)
WO (1) WO2007003420A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407556C (fr) * 2000-05-19 2011-06-21 Genentech, Inc. Analyse de detection genique permettant d'ameliorer la probabilite d'une reponse efficace a une therapie du cancer basee sur un antagoniste d'erbb
DK1771482T3 (da) * 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
WO2006039486A2 (fr) 2004-10-01 2006-04-13 The Board Of Trustees Of The Leland Stanford Junior University Agencements d'imagerie et procedes associes
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1850874B1 (fr) 2005-02-23 2013-10-16 Genentech, Inc. Extension de la periode menant à la progression de la maladie ou à la survie chez les patients atteints du cancer de l'ovaire par le pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
WO2007092581A2 (fr) 2006-02-07 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Procédé de correction d'aberrations optiques
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
IL301603A (en) 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
MX368259B (es) 2013-04-16 2019-09-25 Genentech Inc Variantes de pertuzumab y su evaluacion.
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
WO2016196373A2 (fr) 2015-05-30 2016-12-08 Genentech, Inc. Procédés de traitement de cancer du sein métastatique her2 positif
WO2017087280A1 (fr) 2015-11-16 2017-05-26 Genentech, Inc. Procédés de traitement d'un cancer positif her2
EP3562844A1 (fr) 2016-12-28 2019-11-06 Genentech, Inc. Traitement du cancer exprimant her2 avancé
TW202508629A (zh) 2017-01-17 2025-03-01 美商建南德克公司 皮下her2抗體調配物
PT3589661T (pt) 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2
WO2018200505A1 (fr) 2017-04-24 2018-11-01 Genentech, Inc. Mutations erbb2/her2 dans le domaine transmembranaire ou juxtamembranaire
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP1400536A1 (fr) * 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
KR20060079258A (ko) 1996-10-18 2006-07-05 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
JP4424987B2 (ja) * 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
WO2004008099A2 (fr) * 2002-07-15 2004-01-22 Genentech, Inc. Procedes d'identification de tumeurs sensibles a un traitement par anticorps anti-erbb2

Also Published As

Publication number Publication date
RU2008103608A (ru) 2009-08-20
JP2008545145A (ja) 2008-12-11
EP1902315A1 (fr) 2008-03-26
IL188317A0 (en) 2008-04-13
BRPI0612591A2 (pt) 2010-11-23
MX2008000277A (es) 2008-03-24
KR20080016939A (ko) 2008-02-22
NO20076662L (no) 2008-04-03
EP2194380A3 (fr) 2010-07-14
TW200741203A (en) 2007-11-01
TWI312864B (en) 2009-08-01
NZ564471A (en) 2010-04-30
MY157955A (en) 2016-08-30
CR9635A (es) 2008-02-20
ECSP088081A (es) 2008-02-20
AR053948A1 (es) 2007-05-23
WO2007003420A1 (fr) 2007-01-11
AU2006265275A1 (en) 2007-01-11
CA2613187A1 (fr) 2007-01-11
EP2194380A2 (fr) 2010-06-09
US20070009976A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
MA29730B1 (fr) Detection d'un antigene cible independamment de la presence ou de l'absence d'un anticorps therapeutique correspondant
Campbell et al. Assessment of specific binding proteins suitable for the detection of paralytic shellfish poisons using optical biosensor technology
FR2917174B1 (fr) Analyse multiple d'echantillons sanguins
MX2009009448A (es) Sensibilidad mejorada de determinacion de perfil de anticuerpos a traves de una colocacion en capas incrementada de anticuerpo reportero.
ATE358274T1 (de) Diagnostisches testverfahren
DE602005013225D1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
WO2010107654A3 (fr) Dispositif à flux divisé pour analyses de partenaires à liaison spécifique
MX2007014815A (es) Metodos de inmunoanalisis mejorados.
WO2001050129A3 (fr) Compensation des signaux non specifiques dans des analyses immunologiques quantitatives
WO2005066612A3 (fr) Detection de biomolecules au moyen de biodetecteurs poreux et spectroscopie raman
ATE289685T1 (de) Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
WO2005041893A3 (fr) Detection des biomarqueurs de l'infarctus aigu du myocarde
WO2007035576A3 (fr) Systeme de biocapteur a resonance plasmonique de surface pour la detection d'antigenes et procede destine a determiner la presence d'antigenes
DK2038430T3 (da) Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf
NO20052161L (no) Analysemetode for hjerte-karsykdom
SG164389A1 (en) Detection of a therapeutic antibody in an experimental animal
WO2004084841A3 (fr) Nouveaux anticorps d'albumine anti-feline et procedes de detection de maladies renales precoces
WO2007024735A3 (fr) Methode et anticorps destines a detecter le nitrofurane
Daniso et al. Development of a point of care (POC) test as an immunobiosensor for okadaic acid detection in mussels
WO2007063326A3 (fr) Dispositif et procede de dosage
WO2006004958A3 (fr) Detection ou mesure d'anticorps par rapport a proteines antigenes dans des tissus ou des echantillons biologiques
ATE413469T1 (de) Rezeptoreinfang-assay
NO20016080L (no) Analyse
WO2001027621A3 (fr) DOSAGE IMMUNOENZYMATIQUE D'INHIBITION (iELISA) PERMETTANT DE DETECTER ET QUANTIFIER LES ANTICORPS PRESENTS DANS DES PRELEVEMENTS BIOLOGIQUES
GB2456690A (en) A method for quantitative detection of diabetes related immunological markers